文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

急性冠脉综合征计划PCI术前负荷剂量阿托伐他汀对主要不良心血管事件的影响:SECURE-PCI随机临床试验

Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

SECURE-PCI多中心双盲安慰剂对照随机试验纳入4191例拟行侵入性管理的ACS患者,比较PCI术前及术后24小时两次80mg阿托伐他汀负荷剂量与安慰剂对30天MACE的影响。结论不支持对未经选择的ACS拟行侵入性管理患者常规使用阿托伐他汀负荷剂量。

要点

  • ACS拟行PCI患者围术期阿托伐他汀80mg负荷两次未显著降低30天MACE。
  • 不推荐对未经选择的ACS拟行侵入性管理患者常规使用负荷剂量阿托伐他汀。

核心结论

  • 在ACS并计划行侵入性管理(PCI)的患者中,围术期阿托伐他汀负荷剂量未降低30天MACE发生率。
  • 这些发现不支持对未经选择的ACS拟行侵入性管理患者常规使用阿托伐他汀负荷剂量。

研究设计与样本

  • 多中心、双盲、安慰剂对照随机临床试验,在巴西53个中心开展。
  • 纳入4191例ACS患者,均经冠状动脉造影评估,若解剖可行则行PCI。
  • 入组时间为2012年4月18日至2017年10月6日,30天结局最终随访于2017年11月6日。
  • 患者随机接受两次80mg阿托伐他汀负荷剂量(n=2087)或匹配安慰剂(n=2104),分别在计划PCI前和术后24小时给药。
  • 所有患者从第二次研究药物给药后24小时起接受阿托伐他汀40mg治疗30天。

主要发现

  • 4191例患者平均年龄61.8岁(SD 11.5),女性1085例(25.9%),4163例(99.3%)完成30天随访。
  • 2710例(64.7%)接受PCI,333例(8%)接受冠状动脉旁路移植术,1144例(27.3%)仅接受药物治疗。
  • 30天时,阿托伐他汀组130例(6.2%)发生MACE,安慰剂组149例(7.1%)发生MACE。
  • 未报告肝衰竭病例;安慰剂组报告3例横纹肌溶解(0.1%),阿托伐他汀组0例。

关键数值与推荐

  • 主要结局MACE定义为30天内全因死亡、心肌梗死、卒中和非计划冠状动脉血运重建的复合终点。
  • 阿托伐他汀负荷方案为两次80mg,分别在计划PCI前和术后24小时给药。
  • 所有患者从第二次研究药物给药后24小时起接受阿托伐他汀40mg治疗30天。

临床怎么用

  • 对于ACS拟行侵入性管理(PCI)的未经选择患者,不应常规给予阿托伐他汀负荷剂量以图降低30天MACE。
  • 研究中的患者均后续接受阿托伐他汀40mg治疗30天,临床可参考该背景治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effects of loading doses of statins on clinical outcomes in patients with acute coronary syndrome (ACS) and planned invasive management remain uncertain. OBJECTIVE: To determine if periprocedural loading doses of atorvastatin decrease 30-day major adverse cardiovascular events (MACE) in patients with ACS and planned invasive management. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled, randomized clinical trial conducted at 53 sites in Brazil among 4191 patients with ACS evaluated with coronary angiography to proceed with a percutaneous coronary intervention (PCI) if anatomically feasible. Enrollment occurred between April 18, 2012, and October 6, 2017. Final follow-up for 30-day outcomes was on November 6, 2017. INTERVENTIONS: Patients were randomized to receive 2 loading doses of 80 mg of atorvastatin (n = 2087) or matching placebo (n = 2104) before and 24 hours after a planned PCI. All patients received 40 mg of atorvastatin for 30 days starting 24 hours after the second dose of study medication. MAIN OUTCOMES AND MEASURES: The primary outcome was MACE, defined as a composite of all-cause mortality, myocardial infarction, stroke, and unplanned coronary revascularization through 30 days. RESULTS: Among the 4191 patients (mean age, 61.8 [SD, 11.5] years; 1085 women [25.9%]) enrolled, 4163 (99.3%) completed 30-day follow-up. A total of 2710 (64.7%) underwent PCI, 333 (8%) underwent coronary artery bypass graft surgery, and 1144 (27.3%) had exclusively medical management. At 30 days, 130 patients in the atorvastatin group (6.2%) and 149 in the placebo group (7.1%) had a MACE (absolute difference, 0.85% [95% CI, -0.70% to 2.41%]; hazard ratio, 0.88; 95% CI, 0.69-1.11; P = .27). No cases of hepatic failure were reported; 3 cases of rhabdomyolysis were reported in the placebo group (0.1%) and 0 in the atorvastatin group. CONCLUSIONS AND RELEVANCE: Among patients with ACS and planned invasive management with PCI, periprocedural loading doses of atorvastatin did not reduce the rate of MACE at 30 days. These findings do not support the routine use of loading doses of atorvastatin among unselected patients with ACS and intended invasive management. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01448642.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Berwanger O, Santucci EV, de Barros E Silva PGM, et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA. 2018. PMID: 29525821. doi:10.1001/jama.2018.2444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。